Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Bristol-Myers initiated with an Equal Weight at Wells Fargo » 16:29
12/08/21
12/08
16:29
12/08/21
16:29
BMY

Bristol-Myers

$57.61 /

+0.5 (+0.88%)

Wells Fargo analyst Mohit…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BMY Bristol-Myers
$57.61 /

+0.5 (+0.88%)

BMY Bristol-Myers
$57.61 /

+0.5 (+0.88%)

11/23/21 Societe Generale
Societe Generale upgrades AbbVie to Buy on better than anticipated execution
11/18/21 BMO Capital
Bristol-Myers initiated with an Outperform at BMO Capital
11/15/21 Evercore ISI
Ventyx Biosciences initiated with an Outperform at Evercore ISI
11/15/21 Jefferies
Jefferies starts Ventyx at Buy based on blockbuster potential
BMY Bristol-Myers
$57.61 /

+0.5 (+0.88%)

BMY Bristol-Myers
$57.61 /

+0.5 (+0.88%)

BMY Bristol-Myers
$57.61 /

+0.5 (+0.88%)

BMY Bristol-Myers
$57.61 /

+0.5 (+0.88%)

Saturday
Periodicals
Bristol stock too cheap, could be ready to rally, Barron's says » 09:35
12/04/21
12/04
09:35
12/04/21
09:35
BMY

Bristol-Myers

$56.30 /

+0.89 (+1.61%)

A healthcare crisis…

A healthcare crisis should have been good for biopharma stocks. Instead, it's been anything but. That may be about to change, Ben Levisohn writes in this week's edition of Barron's. Few pharma companies have been hit as hard as Bristol-Myers, with the stock dropping 11% so far this year amid concerns that it will lose exclusivity on drugs like multiple-myeloma treatment Revlimid in 2022, and cancer treatment Opdivo and blood-clot preventer Eliquis later this decade, the authors notes. But if pharma is cheap, then Bristol, at just seven times 2022 earnings, looks like a bargain-especially if those concerns are overblown, he contends. Reference Link

ShowHide Related Items >><<
BMY Bristol-Myers
$56.30 /

+0.89 (+1.61%)

BMY Bristol-Myers
$56.30 /

+0.89 (+1.61%)

11/23/21 Societe Generale
Societe Generale upgrades AbbVie to Buy on better than anticipated execution
11/18/21 BMO Capital
Bristol-Myers initiated with an Outperform at BMO Capital
11/15/21 Evercore ISI
Ventyx Biosciences initiated with an Outperform at Evercore ISI
11/15/21 Jefferies
Jefferies starts Ventyx at Buy based on blockbuster potential
BMY Bristol-Myers
$56.30 /

+0.89 (+1.61%)

BMY Bristol-Myers
$56.30 /

+0.89 (+1.61%)

BMY Bristol-Myers
$56.30 /

+0.89 (+1.61%)

BMY Bristol-Myers
$56.30 /

+0.89 (+1.61%)

Friday
Hot Stocks
Bristol-Myers: FDA accepts for priority review sBLA for Reblozyl » 07:00
12/03/21
12/03
07:00
12/03/21
07:00
BMY

Bristol-Myers

$55.41 /

+0.46 (+0.84%)

, MRK

Merck

$73.89 /

-0.54 (-0.73%)

Bristol Myers Squibb…

Bristol Myers Squibb (BMY) announced that the U.S. FDA has accepted for priority review the supplemental Biologics License Application for Reblozyl, a first-in-class erythroid maturation agent, for the treatment of anemia in adults with non-transfusion dependent beta thalassemia. The FDA has set a Prescription Drug User Fee Act goal date of March 27, 2022. In addition, the European Medicines Agency has validated the Type II variation for Reblozyl in NTD beta thalassemia. Reblozyl is being co-developed and co-commercialized with Merck & Co. (MRK) following Merck's recent acquisition of Acceleron Pharma. These applications were based on safety and efficacy results from the pivotal Phase 2 BEYOND study evaluating Reblozyl plus best supportive care in patients with NTD beta thalassemia.

ShowHide Related Items >><<
MRK Merck
$73.89 /

-0.54 (-0.73%)

BMY Bristol-Myers
$55.41 /

+0.46 (+0.84%)

BMY Bristol-Myers
$55.41 /

+0.46 (+0.84%)

11/23/21 Societe Generale
Societe Generale upgrades AbbVie to Buy on better than anticipated execution
11/18/21 BMO Capital
Bristol-Myers initiated with an Outperform at BMO Capital
11/15/21 Evercore ISI
Ventyx Biosciences initiated with an Outperform at Evercore ISI
11/15/21 Jefferies
Jefferies starts Ventyx at Buy based on blockbuster potential
MRK Merck
$73.89 /

-0.54 (-0.73%)

11/29/21
Fly Intel: Top five analyst downgrades
11/29/21 Morgan Stanley
Merck price target lowered to $82 from $88 at Morgan Stanley
11/29/21 Morgan Stanley
Pfizer price target raised to $60 from $50 at Morgan Stanley
11/29/21 Citi
Merck downgraded to Neutral from Buy at Citi
MRK Merck
$73.89 /

-0.54 (-0.73%)

BMY Bristol-Myers
$55.41 /

+0.46 (+0.84%)

MRK Merck
$73.89 /

-0.54 (-0.73%)

BMY Bristol-Myers
$55.41 /

+0.46 (+0.84%)

MRK Merck
$73.89 /

-0.54 (-0.73%)

BMY Bristol-Myers
$55.41 /

+0.46 (+0.84%)

MRK Merck
$73.89 /

-0.54 (-0.73%)

BMY Bristol-Myers
$55.41 /

+0.46 (+0.84%)

Over a week ago
Hot Stocks
FDA accepts Bristol-Myers' NDA for deucravacitinib in severe plaque psoriasis » 07:01
11/29/21
11/29
07:01
11/29/21
07:01
BMY

Bristol-Myers

$56.30 /

-0.51 (-0.90%)

The company states:…

The company states: "Bristol Myers announced that the FDA has accepted the New Drug Application and the European Medicines Agency has validated the Marketing Authorization Application for deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis. The FDA has assigned a Prescription Drug User Fee Act, or PDUFA, goal date of September 10, 2022. These latest regulatory milestones are in addition to the NDA acceptance by Japan's Ministry of Health, Labour and Welfare for deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis, pustular psoriasis and erythrodermic psoriasis. The regulatory applications are based on positive results from the pivotal POETYK PSO-1 and POETYK PSO-2 trials, which evaluated once daily deucravacitinib in patients with moderate to severe plaque psoriasis versus placebo and Otezla. Deucravacitinib demonstrated significant and clinically meaningful improvements in skin clearance, symptom burden and quality of life measures compared to placebo and Otezla. Deucravacitinib was well-tolerated with a low rate of discontinuation due to adverse events, with no clinically meaningful lab abnormalities. Primary results were presented at the American Academy of Dermatology Virtual Meeting Experience in April 2021, and additional analyses were presented at the European Academy of Dermatology and Venereology 30th Anniversary Congress in September 2021."

ShowHide Related Items >><<
BMY Bristol-Myers
$56.30 /

-0.51 (-0.90%)

BMY Bristol-Myers
$56.30 /

-0.51 (-0.90%)

11/23/21 Societe Generale
Societe Generale upgrades AbbVie to Buy on better than anticipated execution
11/18/21 BMO Capital
Bristol-Myers initiated with an Outperform at BMO Capital
11/15/21 Evercore ISI
Ventyx Biosciences initiated with an Outperform at Evercore ISI
11/15/21 Jefferies
Jefferies starts Ventyx at Buy based on blockbuster potential
BMY Bristol-Myers
$56.30 /

-0.51 (-0.90%)

BMY Bristol-Myers
$56.30 /

-0.51 (-0.90%)

BMY Bristol-Myers
$56.30 /

-0.51 (-0.90%)

BMY Bristol-Myers
$56.30 /

-0.51 (-0.90%)

Upgrade
Societe Generale upgrades AbbVie to Buy on better than anticipated execution » 07:47
11/23/21
11/23
07:47
11/23/21
07:47
ABBV

AbbVie

$115.68 /

-0.56 (-0.48%)

, BMY

Bristol-Myers

$57.04 /

-0.79 (-1.37%)

Societe Generale analyst…

Societe Generale analyst Justin Smith upgraded AbbVie (ABBV) to Buy from Hold with a price target of $172, up from $111, telling investors that he sees management executing better than he anticipated on two franchises "crucial to its long-term prospects," immuno-inflammation and aesthetics. AbbVie is replacing Bristol Myers Squibb (BMY) as his preferred value call in global large cap pharma given its improved "long-term replacement power," added Smith, who now has "full conviction" in management's long-term guidance for Allergan's aesthetics franchise following the company's Q3 report.

ShowHide Related Items >><<
BMY Bristol-Myers
$57.04 /

-0.79 (-1.37%)

ABBV AbbVie
$115.68 /

-0.56 (-0.48%)

ABBV AbbVie
$115.68 /

-0.56 (-0.48%)

11/23/21 Societe Generale
AbbVie upgraded to Buy from Hold at Societe Generale
11/18/21 Piper Sandler
Vertex downgraded to Neutral at Piper ahead of AbbVie CF data
11/17/21 Truist
AbbVie triple data could be pushed back, says Truist
11/01/21 Morgan Stanley
AbbVie price target raised to $124 from $116 at Morgan Stanley
BMY Bristol-Myers
$57.04 /

-0.79 (-1.37%)

11/18/21 BMO Capital
Bristol-Myers initiated with an Outperform at BMO Capital
11/15/21 Evercore ISI
Ventyx Biosciences initiated with an Outperform at Evercore ISI
11/15/21 Jefferies
Jefferies starts Ventyx at Buy based on blockbuster potential
11/08/21 Wedbush
Wedbush bullish on 2seventy Bio, initiates with an Outperform
BMY Bristol-Myers
$57.04 /

-0.79 (-1.37%)

ABBV AbbVie
$115.68 /

-0.56 (-0.48%)

BMY Bristol-Myers
$57.04 /

-0.79 (-1.37%)

ABBV AbbVie
$115.68 /

-0.56 (-0.48%)

BMY Bristol-Myers
$57.04 /

-0.79 (-1.37%)

ABBV AbbVie
$115.68 /

-0.56 (-0.48%)

BMY Bristol-Myers
$57.04 /

-0.79 (-1.37%)

ABBV AbbVie
$115.68 /

-0.56 (-0.48%)

Hot Stocks
Bristol-Myers announces Market Authorization in Europe for Zeposia » 07:01
11/23/21
11/23
07:01
11/23/21
07:01
BMY

Bristol-Myers

$57.04 /

-0.79 (-1.37%)

Bristol Myers Squibb…

Bristol Myers Squibb announced the European Commission has granted a Marketing Authorization for Zeposia, or ozanimod, for the treatment of adults with moderately to severely active ulcerative colitis, or UC, who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent. Zeposia, an oral medication taken once daily, is a sphingosine 1-phosphate, or S1P, receptor modulator that binds with high affinity selectively to S1P subtypes 1 and 5. Zeposia is the first and only oral S1P receptor modulator approved for UC, and represents a new way of treating this chronic immune-mediated disease.

ShowHide Related Items >><<
BMY Bristol-Myers
$57.04 /

-0.79 (-1.37%)

BMY Bristol-Myers
$57.04 /

-0.79 (-1.37%)

11/18/21 BMO Capital
Bristol-Myers initiated with an Outperform at BMO Capital
11/15/21 Evercore ISI
Ventyx Biosciences initiated with an Outperform at Evercore ISI
11/15/21 Jefferies
Jefferies starts Ventyx at Buy based on blockbuster potential
11/08/21 Wedbush
Wedbush bullish on 2seventy Bio, initiates with an Outperform
BMY Bristol-Myers
$57.04 /

-0.79 (-1.37%)

BMY Bristol-Myers
$57.04 /

-0.79 (-1.37%)

BMY Bristol-Myers
$57.04 /

-0.79 (-1.37%)

BMY Bristol-Myers
$57.04 /

-0.79 (-1.37%)

Conference/Events
BMO Capital biopharmaceuticals analyst holds analyst/industry conference call » 09:49
11/19/21
11/19
09:49
11/19/21
09:49
CADL

Candel Therapeutics

$10.97 /

+0.3 (+2.81%)

, GILD

Gilead

$68.54 /

+0.76 (+1.12%)

, MRTX

Mirati Therapeutics

$141.71 /

+4.29 (+3.12%)

, PFE

Pfizer

$52.23 /

+0.82 (+1.60%)

, BMY

Bristol-Myers

$59.21 /

+0.15 (+0.25%)

, LLY

Eli Lilly

$265.69 /

+4.395 (+1.68%)

, INCY

Incyte

$65.20 /

+0.05 (+0.08%)

, BIIB

Biogen

$257.98 /

+1.29 (+0.50%)

, AMGN

Amgen

$205.24 /

+1.18 (+0.58%)

, REGN

Regeneron

$652.47 /

+3.8 (+0.59%)

, NBIX

Neurocrine

$87.03 /

-0.48 (-0.55%)

, VRTX

Vertex Pharmaceuticals

$184.23 /

-1.14 (-0.61%)

, MRK

Merck

$82.41 /

-0.65 (-0.78%)

Biopharmaceuticals…

Biopharmaceuticals Analyst Seigerman discusses his recent initiation of the BioPharmaceuticals Sector with companies CADL, GILD, MRTX, PFE, BMY, LLY, INCY, BIIB, AMGN, REGN, NBIX, VRTX, MRK on an Analyst/Industry conference call to be held on November 19 at 10 am. Webcast Link

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$184.23 /

-1.14 (-0.61%)

REGN Regeneron
$652.47 /

+3.8 (+0.59%)

PFE Pfizer
$52.23 /

+0.82 (+1.60%)

NBIX Neurocrine
$87.03 /

-0.48 (-0.55%)

MRTX Mirati Therapeutics
$141.71 /

+4.29 (+3.12%)

MRK Merck
$82.41 /

-0.65 (-0.78%)

LLY Eli Lilly
$265.69 /

+4.395 (+1.68%)

INCY Incyte
$65.20 /

+0.05 (+0.08%)

GILD Gilead
$68.54 /

+0.76 (+1.12%)

CADL Candel Therapeutics
$10.97 /

+0.3 (+2.81%)

BMY Bristol-Myers
$59.21 /

+0.15 (+0.25%)

BIIB Biogen
$257.98 /

+1.29 (+0.50%)

AMGN Amgen
$205.24 /

+1.18 (+0.58%)

CADL Candel Therapeutics
$10.97 /

+0.3 (+2.81%)

11/18/21 BMO Capital
Candel Therapeutics initiated with an Outperform at BMO Capital
08/23/21 UBS
Candel Therapeutics initiated with a Buy at UBS
08/23/21 Jefferies
Candel Therapeutics initiated with a Buy at Jefferies
08/23/21 Credit Suisse
Candel Therapeutics initiated with an Outperform at Credit Suisse
GILD Gilead
$68.54 /

+0.76 (+1.12%)

11/19/21 Barclays
Arcus Biosciences price target raised to $60 from $48 at Barclays
11/18/21 BMO Capital
Gilead upgraded to Outperform from Market Perform at BMO Capital
11/18/21 Piper Sandler
Gilead assumed with a Neutral at Piper Sandler
11/18/21 SVB Leerink
Arcus Biosciences price target raised to $100 from $68 at SVB Leerink
MRTX Mirati Therapeutics
$141.71 /

+4.29 (+3.12%)

11/18/21 BMO Capital
Amgen initiated with a Market Perform at BMO Capital
11/18/21 BMO Capital
Mirati Therapeutics initiated with an Outperform at BMO Capital
09/22/21 Stifel
Mirati Therapeutics initiated with a Buy at Stifel
09/22/21 Citi
Mirati Therapeutics price target raised to $244 from $232 at Citi
PFE Pfizer
$52.23 /

+0.82 (+1.60%)

11/18/21 BMO Capital
Pfizer initiated with an Outperform at BMO Capital
11/18/21 Benchmark
Pfizer's antiviral pill deal raises Benchmark's confidence in Codexis estimates
11/18/21 Piper Sandler
Cardiff investment by Pfizer 'some nice validation,' says Piper Sandler
11/17/21 Benchmark
Trillium Therapeutics downgraded to Hold from Buy at Benchmark
BMY Bristol-Myers
$59.21 /

+0.15 (+0.25%)

11/18/21 BMO Capital
Bristol-Myers initiated with an Outperform at BMO Capital
11/15/21 Evercore ISI
Ventyx Biosciences initiated with an Outperform at Evercore ISI
11/15/21 Jefferies
Jefferies starts Ventyx at Buy based on blockbuster potential
11/08/21 Wedbush
Wedbush bullish on 2seventy Bio, initiates with an Outperform
LLY Eli Lilly
$265.69 /

+4.395 (+1.68%)

11/18/21 BMO Capital
Eli Lilly initiated with an Outperform at BMO Capital
10/27/21 Mizuho
Eli Lilly price target lowered to $272 from $279 at Mizuho
10/11/21
Fly Intel: Top five analyst upgrades
10/11/21 Berenberg
Eli Lilly upgraded to Buy from Hold at Berenberg
INCY Incyte
$65.20 /

+0.05 (+0.08%)

11/18/21 BMO Capital
Incyte initiated with a Market Perform at BMO Capital
10/15/21 Cantor Fitzgerald
Incyte price target lowered to $79 from $104 at Cantor Fitzgerald
10/04/21 Truist
Incyte price target lowered to $95 from $120 at Truist
09/28/21 B. Riley
Syndax collaboration 'significant vote of confidence,' says B. Riley
BIIB Biogen
$257.98 /

+1.29 (+0.50%)

11/18/21 BMO Capital
Biogen initiated with an Outperform at BMO Capital
11/17/21 Cowen
Cowen says Biogen negative vote at CHMP 'disappointing, but far from surprising'
11/17/21 Stifel
Biogen shares weren't really pricing in Europe approval, says Stifel
11/17/21 Piper Sandler
'Hits just keep on coming' for Biogen, says Piper Sandler
AMGN Amgen
$205.24 /

+1.18 (+0.58%)

11/01/21 Oppenheimer
Amgen price target lowered to $272 from $277 at Oppenheimer
10/04/21 Piper Sandler
Amgen's AMG 451 looks competitive with Dupixent, says Piper Sandler
09/23/21 Daiwa
Amgen downgraded to Neutral from Outperform at Daiwa
REGN Regeneron
$652.47 /

+3.8 (+0.59%)

11/18/21 BMO Capital
Regeneron assumed with an Outperform at BMO Capital
11/10/21 Cantor Fitzgerald
Regeneron price target raised to $760 from $700 at Cantor Fitzgerald
11/09/21 Benchmark
Benchmark sees signs Regeneron may be planning large acquisition
11/05/21
Fly Intel: Top five analyst downgrades
NBIX Neurocrine
$87.03 /

-0.48 (-0.55%)

11/18/21 BMO Capital
Neurocrine initiated with an Underperform at BMO Capital
11/17/21
Fly Intel: Top five analyst upgrades
11/17/21 JPMorgan
Neurocrine upgraded to Overweight from Neutral at JPMorgan
11/02/21 Raymond James
Neurocrine price target lowered to $150 from $163 at Raymond James
VRTX Vertex Pharmaceuticals
$184.23 /

-1.14 (-0.61%)

11/18/21 BMO Capital
Vertex Pharmaceuticals initiated with a Market Perform at BMO Capital
11/18/21 Piper Sandler
Vertex downgraded to Neutral at Piper ahead of AbbVie CF data
11/18/21 Piper Sandler
Vertex Pharmaceuticals downgraded to Neutral from Overweight at Piper Sandler
11/08/21 Goldman Sachs
Bluebird Bio downgraded to Sell from Neutral at Goldman Sachs
MRK Merck
$82.41 /

-0.65 (-0.78%)

11/18/21 BMO Capital
Merck initiated with a Market Perform at BMO Capital
11/18/21 Stifel
Insmed fits similar 'profile' to Dicerna in terms of value, says Stifel
11/05/21 Cowen
Pfizer 'looks to have edge' in COVID oral antivirals, says Cowen
11/05/21 Benchmark
Regeneron downgraded to Hold from Buy at Benchmark
VRTX Vertex Pharmaceuticals
$184.23 /

-1.14 (-0.61%)

REGN Regeneron
$652.47 /

+3.8 (+0.59%)

PFE Pfizer
$52.23 /

+0.82 (+1.60%)

NBIX Neurocrine
$87.03 /

-0.48 (-0.55%)

MRTX Mirati Therapeutics
$141.71 /

+4.29 (+3.12%)

MRK Merck
$82.41 /

-0.65 (-0.78%)

LLY Eli Lilly
$265.69 /

+4.395 (+1.68%)

INCY Incyte
$65.20 /

+0.05 (+0.08%)

GILD Gilead
$68.54 /

+0.76 (+1.12%)

CADL Candel Therapeutics
$10.97 /

+0.3 (+2.81%)

BMY Bristol-Myers
$59.21 /

+0.15 (+0.25%)

BIIB Biogen
$257.98 /

+1.29 (+0.50%)

AMGN Amgen
$205.24 /

+1.18 (+0.58%)

  • 11
    Nov
  • 27
    Jul
PFE Pfizer
$52.23 /

+0.82 (+1.60%)

LLY Eli Lilly
$265.69 /

+4.395 (+1.68%)

GILD Gilead
$68.54 /

+0.76 (+1.12%)

BMY Bristol-Myers
$59.21 /

+0.15 (+0.25%)

BIIB Biogen
$257.98 /

+1.29 (+0.50%)

VRTX Vertex Pharmaceuticals
$184.23 /

-1.14 (-0.61%)

REGN Regeneron
$652.47 /

+3.8 (+0.59%)

PFE Pfizer
$52.23 /

+0.82 (+1.60%)

NBIX Neurocrine
$87.03 /

-0.48 (-0.55%)

MRTX Mirati Therapeutics
$141.71 /

+4.29 (+3.12%)

MRK Merck
$82.41 /

-0.65 (-0.78%)

LLY Eli Lilly
$265.69 /

+4.395 (+1.68%)

INCY Incyte
$65.20 /

+0.05 (+0.08%)

GILD Gilead
$68.54 /

+0.76 (+1.12%)

CADL Candel Therapeutics
$10.97 /

+0.3 (+2.81%)

BMY Bristol-Myers
$59.21 /

+0.15 (+0.25%)

BIIB Biogen
$257.98 /

+1.29 (+0.50%)

AMGN Amgen
$205.24 /

+1.18 (+0.58%)

VRTX Vertex Pharmaceuticals
$184.23 /

-1.14 (-0.61%)

REGN Regeneron
$652.47 /

+3.8 (+0.59%)

PFE Pfizer
$52.23 /

+0.82 (+1.60%)

MRK Merck
$82.41 /

-0.65 (-0.78%)

LLY Eli Lilly
$265.69 /

+4.395 (+1.68%)

INCY Incyte
$65.20 /

+0.05 (+0.08%)

GILD Gilead
$68.54 /

+0.76 (+1.12%)

BMY Bristol-Myers
$59.21 /

+0.15 (+0.25%)

BIIB Biogen
$257.98 /

+1.29 (+0.50%)

AMGN Amgen
$205.24 /

+1.18 (+0.58%)

Hot Stocks
Bristol-Myers announces new PDUFA date for mavacamten » 07:00
11/19/21
11/19
07:00
11/19/21
07:00
BMY

Bristol-Myers

$59.06 /

-0.38 (-0.64%)

Bristol Myers Squibb…

Bristol Myers Squibb announced that the U.S. Food and Drug Administration has extended the review of the New Drug Application for mavacamten for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy to April 28, 2022. The FDA notified Bristol Myers Squibb on November 18, 2021 of the extension of the PDUFA date to allow sufficient time to review information pertaining to updates to the proposed Risk Evaluation Mitigation Strategy. A REMS program was included in the initial application for mavacamten. No additional data or studies have been requested.

ShowHide Related Items >><<
BMY Bristol-Myers
$59.06 /

-0.38 (-0.64%)

BMY Bristol-Myers
$59.06 /

-0.38 (-0.64%)

11/18/21 BMO Capital
Bristol-Myers initiated with an Outperform at BMO Capital
11/15/21 Evercore ISI
Ventyx Biosciences initiated with an Outperform at Evercore ISI
11/15/21 Jefferies
Jefferies starts Ventyx at Buy based on blockbuster potential
11/08/21 Wedbush
Wedbush bullish on 2seventy Bio, initiates with an Outperform
BMY Bristol-Myers
$59.06 /

-0.38 (-0.64%)

BMY Bristol-Myers
$59.06 /

-0.38 (-0.64%)

BMY Bristol-Myers
$59.06 /

-0.38 (-0.64%)

BMY Bristol-Myers
$59.06 /

-0.38 (-0.64%)

Initiation
Bristol-Myers initiated with an Outperform at BMO Capital » 16:20
11/18/21
11/18
16:20
11/18/21
16:20
BMY

Bristol-Myers

$59.06 /

-0.38 (-0.64%)

BMO Capital analyst Evan…

BMO Capital analyst Evan Seigerman initiated coverage of Bristol-Myers with an Outperform rating and $72 price target. Strong fundamentals, anchored by the company's immuno-oncology and hematology businesses, are not fully reflected in current valuation, nor is Bristol's margin expansion potential, Seigerman tells investors. He views the setup for the shares as favorable relative to U.S. major pharma and large cap biotechnology peers, the analyst added.

ShowHide Related Items >><<
BMY Bristol-Myers
$59.06 /

-0.38 (-0.64%)

BMY Bristol-Myers
$59.06 /

-0.38 (-0.64%)

11/15/21 Evercore ISI
Ventyx Biosciences initiated with an Outperform at Evercore ISI
11/15/21 Jefferies
Jefferies starts Ventyx at Buy based on blockbuster potential
11/08/21 Wedbush
Wedbush bullish on 2seventy Bio, initiates with an Outperform
11/01/21 Argus
Bristol-Myers cut to Hold at Argus on generic competition threat to Revlimid
BMY Bristol-Myers
$59.06 /

-0.38 (-0.64%)

BMY Bristol-Myers
$59.06 /

-0.38 (-0.64%)

BMY Bristol-Myers
$59.06 /

-0.38 (-0.64%)

BMY Bristol-Myers
$59.06 /

-0.38 (-0.64%)

Periodicals
J&J expects to file for approval of 14 new drugs by 2025, Reuters reports » 12:02
11/18/21
11/18
12:02
11/18/21
12:02
JNJ

Johnson & Johnson

$162.50 /

-0.77 (-0.47%)

, BMY

Bristol-Myers

$58.93 /

-0.51 (-0.86%)

Mathai Mammen, global…

Mathai Mammen, global head of research for Johnson & Johnson's (JNJ) Janssen unit, said that the company anticipates filing for approval of 14 new drugs by 2025 and is projecting average peak sales of $4B a year for each, Reuters' Michael Erman and Julie Steenhuysen report. In particular, Mammen highlighted a drug combination for non-small cell lung cancer, an anticoagulant it is working on with Bristol-Myers (BMY), and a vaccine for respiratory syncytial virus, the authors note. Reference Link

ShowHide Related Items >><<
JNJ Johnson & Johnson
$162.50 /

-0.77 (-0.47%)

BMY Bristol-Myers
$58.93 /

-0.51 (-0.86%)

JNJ Johnson & Johnson
$162.50 /

-0.77 (-0.47%)

11/09/21 Mizuho
Alkermes price target lowered to $33 from $36 at Mizuho
11/08/21 Morgan Stanley
Morgan Stanley bullish on 2seventy Bio, initiates with an Overweight
10/20/21 Raymond James
Johnson & Johnson price target lowered to $178 from $183 at Raymond James
10/20/21 Baird
Intuitive Surgical price target raised to $370 from $350 at Baird
BMY Bristol-Myers
$58.93 /

-0.51 (-0.86%)

11/15/21 Evercore ISI
Ventyx Biosciences initiated with an Outperform at Evercore ISI
11/15/21 Jefferies
Jefferies starts Ventyx at Buy based on blockbuster potential
11/08/21 Wedbush
Wedbush bullish on 2seventy Bio, initiates with an Outperform
11/01/21 Argus
Bristol-Myers cut to Hold at Argus on generic competition threat to Revlimid
JNJ Johnson & Johnson
$162.50 /

-0.77 (-0.47%)

BMY Bristol-Myers
$58.93 /

-0.51 (-0.86%)

JNJ Johnson & Johnson
$162.50 /

-0.77 (-0.47%)

BMY Bristol-Myers
$58.93 /

-0.51 (-0.86%)

JNJ Johnson & Johnson
$162.50 /

-0.77 (-0.47%)

BMY Bristol-Myers
$58.93 /

-0.51 (-0.86%)

JNJ Johnson & Johnson
$162.50 /

-0.77 (-0.47%)

BMY Bristol-Myers
$58.93 /

-0.51 (-0.86%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.